Special Report

*Author for correspondence:

Department of Laboratory Diagnostics, Division of Pharmacogenomics & Therapy Individualiation, University Hospital Centre Zagreb, 10000 Zagreb, Croatia

Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

Search for more papers by this author

Ivana Šušak Sporiš

Department of Neurology, University Hospital Dubrava, 10000 Zagreb, Croatia

Faculty of Dental Medicine & Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia

Search for more papers by this author

Tamara Božina

Department of Medical Chemistry, Biochemistry & Clinical Chemistry, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

Search for more papers by this author

Iva Klarica-Domjanović

Croatian Agency for Medicinal Products & Medical Devices, 10000 Zagreb, Croatia

Search for more papers by this author

Ante Tvrdeić

Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

Search for more papers by this author

Davor Sporiš

Department of Neurology, University Hospital Dubrava, 10000 Zagreb, Croatia

Faculty of Dental Medicine & Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia

Search for more papers by this author

Published Online:7 Oct 2019https://doi.org/10.2217/pgs-2019-0085

View article

Abstract

Seizure control with antiepileptic drugs (AEDs) as well as susceptibility to adverse drug reactions varies among individuals with epilepsy. This interindividual variability is partly determined by genetic factors. However, genetic testing to predict the efficacy and toxicity of AEDs is limited and genetic variability is, as yet, largely unexplainable. Accordingly, genetic testing can only be advised in a very limited number of cases in clinical routine. Currently, by applying different methodologies, many trials have been undertaken to evaluate cost benefits of preventive pharmacogenetic analysis for patients. There is significant progress in sequencing technologies, and focus is on next-generation sequencing-based methods, like exome and genome sequencing. In this review, an overview of the current scientific knowledge considering the pharmacogenetics of AEDs is given.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342(5), 314–319 (2000).
Medline CASGoogle Scholar
2. Canevini MP, De Sarro G, Galimberti CA et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drug, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 51(5), 797–804 (2010).
Medline CASGoogle Scholar
3. Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin. Drug Metab. Toxicol. 11(8), 1269–1279 (2015).
Medline CASGoogle Scholar
4. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50(1), 1–23 (2009).
MedlineGoogle Scholar
5. Thomas RH, Berkovic SF. The hidden genetics of epilepsy clinically important new paradigm. Nat. Rev. Neurol. 10(5), 283–292 (2014).
MedlineGoogle Scholar
6. Stingl JC, Bartels H, Viviani R, Lehmanna ML, Brockmöllere J. Relevance of UDP-glucuronosyl-transferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol. Ther. 141(1), 92–116 (2014).
Medline CASGoogle Scholar
7. Caudle KE, Rettie AE, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin. Pharmacol. Ther. 96(5), 542–548 (2014). •• Recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype.
Medline CASGoogle Scholar
8. Chung WH, Chang WC, Lee YS et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312(5), 525–534 (2014). • Report on the association between CYP2C9*3 polymorphism and phenytoin-related severe cutaneous adverse drug reactions.
MedlineGoogle Scholar
9. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J. Clin. Pharm. Ther. 31(3), 275–282 (2006).
Medline CASGoogle Scholar
10. Goto S, Seo T, Murata T et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther. Drug Monit. 29(1), 118–121 (2007).
Medline CASGoogle Scholar
11. Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci. Lett. 667, 27–39 (2018).
Medline CASGoogle Scholar
12. Okada Y, Seo T, Ishitsu T et al. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Ther. Drug Moni. 30(4), 540–543 (2008).
Medline CASGoogle Scholar
13. Dean L. Brivaracetam therapy and CYP2C19 genotype. In: Medical Genetics Summaries. Pratt VMcLeod HRubinstein WKattman BMalheiro A (Eds). National Center for Biotechnology Information (US), Bethesda, MD, USA, 59–66 (2018).
Google Scholar
14. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 26, 530–534 (2004).
MedlineGoogle Scholar
15. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr. Clin. Pharmacol. 2(1), 93–109 (2007).
Medline CASGoogle Scholar
16. Ganoci L, Božina T, Mirošević Skvrce N, Lovrić M, Mas P, Božina N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug Metab. Pers. Ther. 32, 11–21 (2017).
Medline CASGoogle Scholar
17. Dean L. Lacosamide therapy and CYP2C19 genotype. In: Medical Genetics Summaries. Pratt VMcLeod HRubinstein WKattman BMalheiro A (Eds). National Center for Biotechnology Information (US), Bethesda, MD, USA, 215–218 (2012–2018).
Google Scholar
18. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Meta. 9(4), 310–322 (2008).
Medline CASGoogle Scholar
19. Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91, 1044–1052 (2012).
Medline CASGoogle Scholar
20. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42(4), 299–305 (2003).
Medline CASGoogle Scholar
21. García-Martín E. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71(3), 196–204 (2002).
Medline CASGoogle Scholar
22. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J. Toxicol. Sci. 38(3), 349–354 (2013).
Medline CASGoogle Scholar
23. Lilja J. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68(4), 384–390 (2000).
Medline CASGoogle Scholar
24. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “missing heritability” problem. Front. Genet. 4, 12 (2013).
Medline CASGoogle Scholar
25. Puranik YG, Birnbaum AK, Marino SE et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14(1), 35–45 (2013).
CASGoogle Scholar
26. Nakajima Y, Saito Y, Shiseki K et al. Hyplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur. J. Clin. Pharmacol. 61(1), 25–34 (2005).
Medline CASGoogle Scholar
27. Yun W, Zhang F, Hu C et al. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res. 107(3), 231–237 (2013).
Medline CASGoogle Scholar
28. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics 15(15), 1867–1879 (2014).
CASGoogle Scholar
29. Ghodke-Puranik Y, Thorn CF, Lamba JK et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics 23(4), 236–241 (2013).
Medline CASGoogle Scholar
30. Wang P, Lin XQ, Cai WK et al. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur. J. Clin. Pharmacol. 74(4), 433–442 (2018).
Medline CASGoogle Scholar
31. Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 3(6), 335–342 (2003).
Medline CASGoogle Scholar
32. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 95(1-2), 1–8 (2011). • Report on the association of the UGT142T>G polymorphism and lower serum concentrations of lamotrigine.
Medline CASGoogle Scholar
33. Ma CL, Wu XY, Jiao Z, Hong Z, Wu ZY, Zhong MK. SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics 16(4), 347–360 (2015).
CASGoogle Scholar
34. Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin. Drug Metab. Toxicol. 10, 1337–1354 (2014).
Medline CASGoogle Scholar
35. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 58(2), 140–161 (2006).
Medline CASGoogle Scholar
36. Potschka H, Brodie MJ. Pharmacoresistance. Handb. Clin. Neurol. 108, 741–757 (2012).
MedlineGoogle Scholar
37. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442–1448 (2003).
Medline CASGoogle Scholar
38. Manna I, Gambardella A, Labate A et al. Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1 C3435T and response to antiepileptic drug treatment in temporal lobe epilepsy. Seizure 24, 124–126 (2015).
MedlineGoogle Scholar
39. Sills GJ, Mohanraj R, Butler E et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46(5), 643–647 (2005).
Medline CASGoogle Scholar
40. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 12(5), 713–725 (2011).
CASGoogle Scholar
41. Orlandi A, Paolino MC, Striano P, Parisi P. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. Expert Opin. Drug Metab. Toxicol. 14(5), 505–512 (2018).
Medline CASGoogle Scholar
42. Qian L, Fang S, Yan YL, Zeng SS, Xu ZJ, Gong ZC. The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: a meta-analysis. J. Clin. Neurosci. 37, 6–14 (2017).
Medline CASGoogle Scholar
43. Wang Y, Tang L, Pan J et al. The recessive model of MPR2 G1249A polymorphism decrease the risk of drug-resistant in Asian epilepsy: a systematic review and meta-analysis. Epilepsy Res. 112, 56–63 (2015).
Medline CASGoogle Scholar
44. Chen J, Su QB, Tao YQ et al. ABCC2 rs2273697 is associated with valproic acid concentrations in patients with epilepsy on valproic acid monotherapy. Pharmazie 73(5), 279–282 (2018).
Medline CASGoogle Scholar
45. Klarica Domjanović I, Lovrić M, Trkulja V et al. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br. J. Clin. Pharmacol. 84(9), 2106–2119 (2018). • This is first study indicating a potentially relevant interaction between ABCG2 421C>A polymorphism and valproate in their effects on lamotrigine disposition.
MedlineGoogle Scholar
46. Basic S, Hajnsek S, Bozina N et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood–brain barrier in patients with generalized epilepsy. Seizure 17(6), 524–530 (2008).
MedlineGoogle Scholar
47. Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102(15), 5507–5512 (2005).
Medline CASGoogle Scholar
48. Zhou BT, Zhou QH, Yin JY et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci. Ther. 18(7), 566–572 (2012).
Medline CASGoogle Scholar
49. Shi L, Zhu M, Li H et al. SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients. Eur. J. Clin. Pharmacol. 75(5), 655–663 (2019).
Medline CASGoogle Scholar
50. Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z. SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14(10), 1153–1166 (2013).
CASGoogle Scholar
51. Markovic I, Pejanovic-Skobic N, Bozina N, Susak-Sporis I, Sporis D, Basic S. The lack of influence of IVS5-91 G>A polymorphism of the SCN1A gene on efficacy of lamotrigine in patients with focal epilepsy. Neurol. Res. 1–6 (2019). doi:10.1080/01616412.2019.1635321 (Epub ahead of print).
MedlineGoogle Scholar
52. Franco V, Perucca E. The pharmacogenomics of epilepsy. Expert Rev. Neurother. 15(10), 1161–1170 (2015).
Medline CASGoogle Scholar
53. Qu J, Zhang Y, Yang ZQ et al. Gene-wide tagging study of the association between KCNT1 polymorphisms and the susceptibility and efficacy of genetic generalized epilepsy in Chinese population. CNS Neurosci. Ther. 20(2), 140–146 (2014).
Medline CASGoogle Scholar
54. Lynch JM, Tate SK, Kinirons P et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res. 83(1), 44–51 (2009).
Medline CASGoogle Scholar
55. Leen WG, Klepper J, Verbeek MM et al. Glucose transporter-1-deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 133(3), 655–670 (2010).
MedlineGoogle Scholar
56. Mills PB, Struys E, Jakobs C et al. Mutations in individuals with pyridoxine-dependent seizures. Nat. Med. 12(3), 307–309 (2006).
Medline CASGoogle Scholar
57. Perucca P, Perucca E. Identifying mutations in epilepsy genes. Impact on treatment selection. Epilepsy Res. 152, 18–30 (2019).
Medline CASGoogle Scholar
58. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K⁺ channel opener for the treatment of epilepsy. Epilepsia 53(3), 412–424 (2012).
Medline CASGoogle Scholar
59. Pierson TM, Yuan H, Marsh ED et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann. Clin. Transl. Neurol. 1(3), 190–198 (2014).
Medline CASGoogle Scholar
60. Fricke-Galindo I, Llerena A, López-López M. An update on HLA alleles associated with adverse drug reactions. Drug Metab. Pers. Ther. 32(2), 73–87 (2017).
Medline CASGoogle Scholar
61. Mullan KA, Anderson A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA associated antiepileptic drug-induced cutaneous adverse reactions. HLA 93(6), 417–435 (2019).
Medline CASGoogle Scholar
62. Chen CB, Abe R, Pan RY et al. An updated review of the molecular mechanisms in drug hypersensitivity. J. Immunol. Res. 2018, 6431694 (2018).
MedlineGoogle Scholar
63. Chung WH, Hung SI, Hong HS et al. A marker for Stevens–Johnson syndrome. Nature 428(6982), 486 (2004). •• First report on the strong association between a genetic marker, HLA–B*1502, and Stevens–Johnson syndrome induced by carbamazepine.
Medline CASGoogle Scholar
64. Liu Y, Yu Y, Nie X, Zhao L, Wang X. Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis. Pharmacogenomics 19(6), 547–552 (2018).
CASGoogle Scholar
65. Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034–1041 (2011).
Medline CASGoogle Scholar
66. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134–1143 (2011). • Report on the contribution of the of HLA-A*31:01 to the pathogenesis of carbamazepine-induced hypersensitivity reactions.
Medline CASGoogle Scholar
67. Plumpton CO, Yip VL, Alfirevic A, Marson AG, Pirmohamed M, Hughes DA. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia 56, 556–563 (2015).
MedlineGoogle Scholar
68. Saneto RP, Lee IC, Koenig MK et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 19(3), 140–146 (2010). •• Report on the mutations in POLG and the risk of sodium valproate-induced liver toxicity.
MedlineGoogle Scholar
69. Ingelman-Sundberg M, Cascorbi I. Pharmacogenomic or epigenomic biomarkers in drug treatment: two sides of the same medal? Clin. Pharmacol. Ther. 99, 478–480 (2016).
Medline CASGoogle Scholar
70. Navarrete-Modesto V, Orozco-Suárez S, Feria-Romero IA, Rocha L. The molecular hallmarks of epigenetic effects mediated by antiepileptic drugs. Epilepsy Res. 149, 53–65 (2019).
Medline CASGoogle Scholar
71. Kozyra M, Ingelman-Sundberg M, Lauschke V. Rare genetic variants in cellular transporters, metabolic enzymes and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. 19, 20–29 (2017). •• Significance of rare genetic variants for the overall pharmacogenomics variability.
Medline CASGoogle Scholar
72. US Food and Drug Association. Table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov.
Google Scholar

Vol. 20, No. 15

Metrics

Downloaded 606 times

History

Received 14 June 2019

Accepted 12 August 2019

Published online 7 October 2019

Published in print October 2019

Information

Keywords

Author contributions

The manuscript is submitted with the knowledge and on behalf of the listed coauthors. The authors certify that each coauthor listed above participated sufficiently in the work to take responsibility for the content, and that all those who qualify are listed. Božina N: substantial contributions to the conception and design of the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy and integrity of any part of the work are appropriately investigated and resolved. I Šušak-Sporiš, T Božina,I Klarica-Domjanović, A Tvrdeić and D Sporišr: Substantial contributions to the conception of the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy and integrity of any part of the work are appropriately investigated and resolved.

Financial & competing interests disclosure

The authors have nothing to declare. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Pharmacogenetics and the treatment of epilepsy: what do we know?

Abstract

References